Navigation Links
PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference
Date:10/6/2008

MONTEREY, Calif., Oct. 6 /PRNewswire/ -- Today, PARI Pharma GmbH will unveil a prototype Closed System using eFlow Technology that uses single dose ampoules to control medication used in the nebulizer system. By creating a proprietary, unit-dose ampoule that is required to operate the nebulizer, the Closed System using eFlow Technology meets an unmet need by reducing the risk of using the wrong medication in the delivery device, simplifying filling procedures, improving dose uniformity and hygiene.

"This is a very exciting period in inhalation drug development. Building on our ability to customize a delivery device and a medication formulation, we have been able to take eFlow Technology a step further by creating an aerosol device that will only deliver its matching formulation. This has a number of advantages for our pharmaceutical partners, physicians, and patients. The Closed System using eFlow Technology takes away the risk of someone putting anything other than their prescribed medication into an advanced delivery device, while keeping medication sealed until it is opened in the nebulizer," said Geoff A. Hunziker, president of eFlow LLC. "As new device technologies develop, it is critical for safety and efficacy to ensure patients use the approved delivery device for the inhaled drug."

Thomas Gallem, director of product design of PARI Pharma, will present "Development of a closed, ampoule-based electronic nebulizer system -- next step in drug-device combination for liquid aerosol therapy" at the 22nd Annual Medical Plastics Conference in Copenhagen, Denmark today.

PARI Pharma is currently in discussions about introducing the Closed System using eFlow Technology into new clinical development programs with pharmaceutical partners.

About eFlow Technology

eFlow Technology enables extremely efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments. eFlow Technology and products based on it are proprietary to PARI Pharma.

PARI Pharma partners with pharmaceutical companies to develop new or improved therapies with eFlow Technology and other advanced delivery platforms. Investigational eFlow Nebulizer Systems are optimized per investigational drug product and are currently in clinical trials for asthma, cystic fibrosis, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications.

About PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices and therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration optimized with advanced delivery technologies, such as eFlow Technology.

PARI Pharma provides comprehensive inhalation drug development, including nebulizer formulation development and optimization, CMC, analytics, aerosol characterization, clinical protocol development, and regulatory guidance. PARI Pharma has several clinical development programs ongoing, either partnered or on its own. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany with a major presence in the United States. Online at http://www.paripharma.com

Additional information on eFlow Technology is available by contacting Kirsten Ayars at 805-452-7909 or Geoff A. Hunziker at 831-372-3580.


'/>"/>
SOURCE PARI Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... by the American Association of Integrative Medicine and available for application on Saturday, ... the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president of AutismOne, ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment Center® ... March 13-16, was a busy spot this year. Liz Solovay and Adrian Picheny, ... preventing outbreaks among camp communities during the upcoming 2017 camping season. “Lice infestations ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people ... has a lot to offer to the discussion of dealing with excess skin oil. “Oily ... are many home remedies that can help remove the oily shine while keeping the skin ...
(Date:3/28/2017)... ... ... adventure that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the creation of ... of him that he had neglected to do, but this was from God and there ... who would have felt themselves to be special and better than others due to the ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... for clear braces. People who want straight teeth without the extensive time commitment ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually invisible ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... YORK , March 28, 2017 ... investors, attention to these four stocks: The Medicines ... Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals ... operate in the Generic Drugs space which is ... drugs. The key growth drivers for the industry are ...
(Date:3/28/2017)... ROCKVILLE, Md. , March 28, 2017 /PRNewswire/ ... dedicated to innovative therapeutics addressing cancer and other ... at the American Association for Cancer Research annual ... April 3 is entitled "Evaluation of ENMD-2076 ... and the second poster to be presented ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
Breaking Medicine Technology: